Matthew R Gardner

List of Publications by Year in Descending Order

22 papers	562 citations	13 h-index	22 g-index
22 ext. papers	756 ext. citations	11.6 avg, IF	3.77 L-index

#	Paper	IF	Citations
22	Estimation of the in vivo neutralization potency of eCD4Ig and conditions for AAV-mediated production for SHIV long-term remission.. *Science Advances*, **2022**, 8, eabj5666	14.3	
21	High concordance of ELISA and neutralization assays allows for the detection of antibodies to individual AAV serotypes.. *Molecular Therapy - Methods and Clinical Development*, **2022**, 24, 199-206	6.4	2
20	Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2. *PLoS Pathogens*, **2021**, 17, e1009501	7.6	20
19	A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies. *MBio*, **2020**, 11,	7.8	19
18	Promise and Progress of an HIV-1 Cure by Adeno-Associated Virus Vector Delivery of Anti-HIV-1 Biologics. *Frontiers in Cellular and Infection Microbiology*, **2020**, 10, 176	5.9	9
17	Mutations from bat ACE2 orthologs markedly enhance ACE2-Fc neutralization of SARS-CoV-2 **2020**,		16
16	Anti-drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing Antibodies. *Molecular Therapy*, **2019**, 27, 650-660	11.7	25
15	eCD4-Ig Limits HIV-1 Escape More Effectively than CD4-Ig or a Broadly Neutralizing Antibody. *Journal of Virology*, **2019**, 93,	6.6	15
14	Associating HIV-1 envelope glycoprotein structures with states on the virus observed by smFRET. *Nature*, **2019**, 568, 415-419	50.4	92
13	AAV-delivered eCD4-Ig protects rhesus macaques from high-dose SIVmac239 challenges. *Science Translational Medicine*, **2019**, 11,	17.5	20
12	A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies. *Journal of Virology*, **2019**, 93,	6.6	1
11	eCD4-Ig Variants That More Potently Neutralize HIV-1. *Journal of Virology*, **2018**, 92,	6.6	16
10	Conditional Regulation of Gene Expression by Ligand-Induced Occlusion of a MicroRNA Target Sequence. *Molecular Therapy*, **2018**, 26, 1277-1286	11.7	15
9	Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies. *PLoS Pathogens*, **2018**, 14, e1007238	7.6	9
8	Engineering antibody-like inhibitors to prevent and treat HIV-1 infection. *Current Opinion in HIV and AIDS*, **2017**, 12, 294-301	4.2	14
7	Simian Immunodeficiency Virus SIVmac239, but Not SIVmac316, Binds and Utilizes Human CD4 More Efficiently than Rhesus CD4. *Journal of Virology*, **2017**, 91,	6.6	3
6	eCD4-Ig promotes ADCC activity of sera from HIV-1-infected patients. *PLoS Pathogens*, **2017**, 13, e1006786	7.6	19

List of Publications

5	CD4-Induced Antibodies Promote Association of the HIV-1 Envelope Glycoprotein with CD4-Binding Site Antibodies. *Journal of Virology*, **2016**, 90, 7822-32	6.6	13
4	AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. *Nature*, **2015**, 519, 87-91	50.4	211
3	A double-mimetic peptide efficiently neutralizes HIV-1 by bridging the CD4- and coreceptor-binding sites of gp120. *Journal of Virology*, **2014**, 88, 3353-8	6.6	13
2	Direct expression and validation of phage-selected peptide variants in mammalian cells. *Journal of Biological Chemistry*, **2013**, 288, 18803-10	5.4	9
1	Enhanced recognition and neutralization of HIV-1 by antibody-derived CCR5-mimetic peptide variants. *Journal of Virology*, **2012**, 86, 12417-21	6.6	21